About Medeor Therapeutics


MEDEOR THERAPEUTICS is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies. Our growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Our pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). We hold exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.

Learn About The Holy Grail

Senior Management

Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery...
Read More

Steven R. Deitcher, M.D.

Founder, President, CEO, and Board Member
Dr. Weber joined Medeor Therapeutics in 2016 to lead all global regulatory and quality efforts related to MDR-101. He has more than 20 years of regulatory affairs experience with biological products. Previously, he was Executive Vice President of Global Regulatory Affairs and Quality Management for Mesoblast LTD. Prior to joining Mesoblast...
Read More

Darin J. Weber, Ph.D.

Senior Vice President, Regulatory Affairs & Quality
Dr. Read joined Medeor Therapeutics in 2015 to lead MDR-101 product development efforts ranging from donor stem cell collection to commercial manufacturing and final product delivery to patients. She has more than 20 years of product development experience with biological products. Previously, Dr. Read held cell therapy ...
Read More

Elizabeth "EJ" Read, M.D.

Senior Vice President, Product Development
Dr. Batty joined Medeor Therapeutics in 2016 as Chief Medical Officer to lead the clinical development and medical affairs efforts related to Medeor's organ transplantation programs. Previously, Scott held an executive management role at ImmunArray as well as leadership roles in transplant and stem cell product clinical development ...
Read More

D. Scott Batty, Jr., M.D

Chief Medical Officer

Learn More About Our Board Members